Sridhar K. Rabindran

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann, Luis Paz‐Ares, Bogdan Żurawski et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Eunice L. Kwak, Raffaella Sordella, Daphne W. Bell et al. · Proceedings of the National Academy of Sciences · 2005 · 952 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Mieke Schutte, Ralph H. Hruban, Joseph Geradts et al. · PubMed · 1997 · 665 citations

Medicine, Genetics, Oncology +17

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Sridhar K. Rabindran, Carolyn Discafani, Edward Rosfjord et al. · Cancer Research · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1<i>H</i>-indol-5-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng et al. · Journal of Medicinal Chemistry · 2012 · 619 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13